Clinical Trial Update: Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating antibody-mediated IL-6 inhibition to reduce inflammation in patients with advanced chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Inflammation

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Chronic Kidney Disease, Inflammation | Phase 2 | Status: COMPLETED